CLEVELAND BIOLABS INC

Form 4

October 19, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

Check this box

3235-0287 Number: January 31, Expires: 2005

OMB APPROVAL

if no longer subject to Section 16. Form 4 or

Estimated average

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

burden hours per response... 0.5

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** Gudkov Andrei V			2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
			CLEVELAND BIOLABS INC [CBLI]	(Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	_X_ Director 10% Owner _X_ Officer (give title Other (specify		
73 HIGH STREET			10/16/2009	below) below) Chief Scientific Officer		
	(Street)	eet)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
DUEEN O NV 14202			Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Form filed by More than One			
BUFFALO, NY 14203				Person		
(City)	(State)	(Zip)	Table I. Non Don't of a Country of			

(City)	(State) (A	Table Table	I - Non-Do	erivative	Securi	ities Acq	uired, Disposed o	of, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	action Date 2A. Deemed		4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)			Securities I Beneficially (Owned I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	10/16/2009		S <u>(1)</u>	100	D	\$ 4.77	1,544,500	D	
Common Stock	10/16/2009		S(1)	4,600	D	\$ 4.76	1,539,900	D	
Common Stock	10/16/2009		S <u>(1)</u>	300	D	\$ 4.72	1,539,600	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

Edgar Filing: CLEVELAND BIOLABS INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	B) [5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code	V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (Right to Buy)	\$ 8.36						04/06/2007	04/05/2017	Common Stock	37,500
Employee Stock Options (Right to Buy)	\$ 4						02/04/2008	02/03/2018	Common Stock	137,250

Reporting Owners

Reporting Owner Name / Address	Relationships						
Fg	Director	10% Owner	Officer	Other			
Gudkov Andrei V 73 HIGH STREET BUFFALO, NY 14203	X		Chief Scientific Officer				

Signatures

/s/ Andrei V
Gudkov

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.3% of the reporting person's 1,549,600 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 3.9% of the reporting person's shares held prior to adoption of the plan.

Reporting Owners 2

Edgar Filing: CLEVELAND BIOLABS INC - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.